Evidence map›Paper›PMID 36928117›Full record

ArticleThe Journal of clinical investigation2023

Keratinocytes sense and eliminate CRISPR DNA through STING/IFN-κ activation and APOBEC3G induction.

Mrinal K Sarkar, Ranjitha Uppala, Chang Zeng, Allison C Billi, Lam C Tsoi, Austin Kidder, Xianying Xing, Bethany E Perez White, Shuai Shao, Olesya Plazyo and 7 more

Open access · goldAbstract read
In one paragraph

Article in The Journal of clinical investigation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Decoding Undesirable Inflammatory Responses of Nucleic Acid-Delivering Lipid Nanoparticles.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 2 countries.

Mrinal K SarkarDepartment of Dermatology, and.
Ranjitha UppalaDepartment of Dermatology, and.
Chang ZengDepartment of Dermatology, and.
Allison C BilliDepartment of Dermatology, and.
Lam C TsoiDepartment of Dermatology, and.
Austin KidderDepartment of Dermatology, and.
Xianying XingDepartment of Dermatology, and.
Bethany E Perez WhiteDepartment of Dermatology, Northwestern University, Chicago, Illinois, USA.
Shuai ShaoDepartment of Dermatology, and.
Olesya PlazyoDepartment of Dermatology, and.
Sirisha SirobhushanamDepartment of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA.
Enze XingDepartment of Dermatology, and.
Yanyun JiangDepartment of Dermatology, and.
Katherine A GallagherSection of Vascular Surgery, Department of Surgery.
John J VoorheesDepartment of Dermatology, and.
J Michelle KahlenbergDepartment of Dermatology, and.
Johann E GudjonssonDepartment of Dermatology, and.
University of Michigan · USChinese Academy of Medical Sciences & Peking Union Medical College · CNNorthwestern University · USXijing Hospital · CN

Funding

University of Michigan Skin Biology and Diseases Resource-based CenterP30AR075043 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ANDRZEJ A. DLUGOSZ · 2019 to 2026
$6.6M
Characterization of Interferon Kappa as a Novel Target in Cutaneous LupusR01AR071384 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Joanne Michelle Kahlenberg · 2017 to 2026
$3.6M
Role of IL-13 and the IL-13 Associated rs20541 Risk Variant in the Pathogenesis of PsoriasisR01AR069071 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GUDJONSSON, JOHANN ELI · 2015 to 2019
$2.1M
Linking Disease Mechanisms and Outcomes in Rheumatic DiseasesK24AR076975 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Joanne Michelle Kahlenberg · 2020 to 2026
$910k
Mechanisms of sex discrepancy in autoimmune disease: Regulation of the female-biased VGLL3 immune pathwayK08AR078251 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BILLI, ALLISON CHELSA · 2021 to 2025
$865k
Role of the Psoriasis Associated IL23R Risk Variants on Th17 Biology and FunctionK08AR060802 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GUDJONSSON, JOHANN ELI · 2011 to 2015
$636k
Integrative Biology Approach to Identify and Characterize Roles of lncRNAs Associated with Psoriasis PathologyK01AR072129 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI TSOI, LAM CHEUNG · 2017 to 2021
$500k
Epigenetic regulation of sexually dimorphic immune responses in keratinocytesR21AR077741 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GUDJONSSON, JOHANN ELI · 2021 to 2022
$376k
NIAMS NIH HHS K01 AR072129NIAMS NIH HHS K08 AR060802NIAMS NIH HHS K24 AR076975NIAMS NIH HHS P30 AR075043NIAMS NIH HHS R01 AR069071NIAMS NIH HHS R01 AR071384NIAMS NIH HHS R21 AR077741
6 · The paper itself

Abstract

CRISPR/Cas9 has been proposed as a treatment for genetically inherited skin disorders. Here we report that CRISPR transfection activates STING-dependent antiviral responses in keratinocytes, resulting in heightened endogenous interferon (IFN) responses through induction of IFN-κ, leading to decreased plasmid stability secondary to induction of the cytidine deaminase gene APOBEC3G. Notably, CRISPR-generated KO keratinocytes had permanent suppression of IFN-κ and IFN-stimulated gene (ISG) expression, secondary to hypermethylation of the IFNK promoter region by the DNA methyltransferase DNMT3B. JAK inhibition via baricitinib prior to CRISPR transfection increased transfection efficiency, prevented IFNK promoter hypermethylation, and restored normal IFN-κ activity and ISG responses. This work shows that CRISPR-mediated gene correction alters antiviral responses in keratinocytes, has implications for future gene therapies for inherited skin diseases using CRISPR technology, and suggests pharmacologic JAK inhibition as a tool for facilitating and attenuating inadvertent selection effects in CRISPR/Cas9 therapeutic approaches.

Indexed as

Interferon Type IAntiviral AgentsAPOBEC DeaminasesDNAHumansKeratinocytesSTING ProteinAntiviral AgentsAPOBEC3 proteins, humanAPOBEC DeaminasesDNAinterferon kappaInterferon Type ISTING1 protein, humanSTING ProteinCell BiologyCytokinesDermatologyGene therapySkin

Identifiers

PMID36928117
PMCPMC10145927
OpenAlexW4327626301

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.